HS-10353 vs KH607

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: GABA-A receptor · full Major Depressive Disorder pipeline

HS-10353

Developed by Hansoh Pharmaceutical Group

Phase 2 in Major Depressive Disordersmall molecule
Weak signal

NCT05195203 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Endpoints of the trial:AE,SAE". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Endpoints of the trial:AE,SAE (Baseline to end of follow-up (a maximum of 20 days)): Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses

Result source: NCT05195203

KH607

Developed by Chengdu Kanghong Pharmaceutical

Phase 3 in Major Depressive Disordersmall molecule
Partial signal

NCT07101120 · Phase 2 · completed

The study was randomized, quadruple-blind and placebo-controlled, with 126 participants, and used the clinical HAM-D17 score as its primary endpoint. The sponsors reported on 15 May 2026 that the study met its primary endpoint; they released no effect size, and the registry has no posted results, so the evidence is moderate.

Result as reported by the sponsors (15 May 2026 release); no effect size released and no results posted on ClinicalTrials.gov.

Next expected readout: December 2027 · NCT07741240 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHS-10353KH607
MADRS, change (acute)—Not reported—Trial running · NCT07741240
CGI-S, change (acute)—Not reported—Trial running · NCT07741240
MADRS response—Not reported—Trial running · NCT07741240
MADRS remission—Not reported—Trial running · NCT07741240
Relapse (% of patients)—Not reported—Trial running · NCT07741240

MADRS, change (acute)

HS-10353
—Not reported
KH607
—Trial running · NCT07741240

CGI-S, change (acute)

HS-10353
—Not reported
KH607
—Trial running · NCT07741240

MADRS response

HS-10353
—Not reported
KH607
—Trial running · NCT07741240

MADRS remission

HS-10353
—Not reported
KH607
—Trial running · NCT07741240

Relapse (% of patients)

HS-10353
—Not reported
KH607
—Trial running · NCT07741240
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

KH607: no structured comparison results are available for Major Depressive Disorder.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HS-10353
Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses NCT05195203 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-10353's landscape · KH607's landscape